The Therapeutic Antibody Discovery Company
AR Pharma?s lead compound AR2201 was developed at Dana Farber Cancer Institute and has been published in the peer-reviewed journal mAbs. The company expects to take the compound into Phase I trials within 12 months to treat B-cell chronic lymphocytic leukemia (B-CLL), the most common leukemia in the United States, accounting for approximately 30% of all adult leukemia cases. AR2201 is a monoclonal antibody (mAbs) designed to bring the benefits of cutting edge, personalized medicine to that portion of patients whose B-CLL expresses a particular germ line gene. The compound also shows promise for the treatment of several immune disorders.